MUC-1 Regulates MiR34a Expression in Acute Myeloid Leukemia Cells Resulting in an Accumulation of Granulocytic Myeloid-Derived Suppressor Cells
Athalia R. Pyzer, David Avigan(Beth Israel Deaconess Medical Center), Robin Joyce(Beth Israel Deaconess Medical Center), Rebecca Karp Leaf(California University of Pennsylvania), Maxwell Coll, Hasan Rajabi(Harvard University), Jacalyn Rosenblatt(Beth Israel Deaconess Medical Center), Poorvi Somaiya Dutt(Beth Israel Deaconess Medical Center), Katarina Luptakova(Tesaro (United States)), Donald Küfe(Dana-Farber Cancer Institute), Malgorzata McMasters(Beth Israel Deaconess Medical Center), Myrna Nahas, Salvia Jain(Broad Institute), Michal Bar‐Natan(NewYork–Presbyterian Hospital), Dina Stroopinsky(Beth Israel Deaconess Medical Center), James D. Levine(Beth Israel Deaconess Medical Center), Kristen Palmer(Beth Israel Deaconess Medical Center), Ashujit Tagde(Dana-Farber Cancer Institute), Abigail Washington(Beth Israel Deaconess Medical Center), Jon Arnason(Beth Israel Deaconess Medical Center)
Cited by 0
Related Papers
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2019|1.7k
Randomized Controlled Trial of Yttrium-90–Labeled Ibritumomab Tiuxetan Radioimmunotherapy Versus Rituximab Immunotherapy for Patients With Relapsed or Refractory Low-Grade, Follicular, or Transformed B-Cell Non-Hodgkin’s Lymphoma
|Journal of Clinical Oncology|2002|1.2k
Interleukin-2 and Regulatory T Cells in Graft-versus-Host Disease
|New England Journal of Medicine|2011|1.1k